New drug duo battles advanced kidney cancer in Head-to-Head trial
Disease control
Terminated
This study is testing a new combination of two immunotherapy drugs (botensilimab and balstilimab) for people newly diagnosed with advanced kidney cancer that has spread. It will compare this new combination to a standard two-drug immunotherapy treatment (ipilimumab and nivolumab)…
Phase: PHASE2 • Sponsor: Michael B. Atkins, MD • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC